Progyny, Inc. (NASDAQ:PGNY) Receives $24.82 Average Price Target from Analysts

Progyny, Inc. (NASDAQ:PGNY) has been given a consensus recommendation of “Hold” by the thirteen research firms that are covering the stock, Marketbeat.com reports. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $24.82.

Several equities analysts have issued reports on PGNY shares. JPMorgan Chase & Co. upped their price objective on shares of Progyny from $17.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Bank of America boosted their target price on Progyny from $21.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, February 11th. Finally, Canaccord Genuity Group raised their price target on Progyny from $17.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, February 28th.

Insider Buying and Selling at Progyny

In related news, CEO Peter Anevski bought 209,500 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were acquired at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This trade represents a 90.32 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman David J. Schlanger purchased 150,000 shares of the business’s stock in a transaction dated Thursday, December 26th. The shares were bought at an average price of $14.68 per share, with a total value of $2,202,000.00. Following the purchase, the chairman now directly owns 228,269 shares of the company’s stock, valued at approximately $3,350,988.92. The trade was a 191.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 12.30% of the stock is owned by company insiders.

Institutional Trading of Progyny

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Signaturefd LLC raised its holdings in Progyny by 1,355.0% during the fourth quarter. Signaturefd LLC now owns 1,455 shares of the company’s stock worth $25,000 after purchasing an additional 1,355 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Progyny by 341.4% during the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company’s stock worth $28,000 after buying an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Progyny by 108.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company’s stock worth $51,000 after buying an additional 1,526 shares in the last quarter. Caitlin John LLC lifted its holdings in shares of Progyny by 2,974.8% in the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company’s stock valued at $57,000 after buying an additional 3,183 shares during the period. Finally, Natixis purchased a new stake in shares of Progyny in the fourth quarter valued at approximately $69,000. Hedge funds and other institutional investors own 94.93% of the company’s stock.

Progyny Trading Up 0.8 %

Shares of Progyny stock opened at $21.86 on Thursday. The company has a fifty day simple moving average of $21.93 and a 200-day simple moving average of $18.59. The stock has a market cap of $1.87 billion, a price-to-earnings ratio of 37.69, a PEG ratio of 2.39 and a beta of 1.41. Progyny has a 12-month low of $13.39 and a 12-month high of $38.98.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.